Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 12
• Langue: English

Extrait

Frost & Sullivan: Next-Generation Sequencing

Services is one of the Fastest Growing Markets

in the Life Sciences Industry

PR Newswire

MOUNTAIN VIEW, California, June 28, 2012

- New applications provide a thrust to this expanding market

MOUNTAIN VIEW, California

,

June 28, 2012

/PRNewswire/ -- The growing list of

applications enabled by next-generation sequencing technology has allowed

sequencing service providers to make inroads into new customer segments and

research fields, such as cancer research, genetic disease research,

metagenomics, newborn sequencing, and clinical sequencing. Researchers

lacking in-house sequencing infrastructure or experience are gaining access to

the latest technologies through service providers offering complete sequencing

workflows.

New analysis from Frost & Sullivan's (http://www.drugdiscovery.frost.com)

Strategic Analysis of the U.S. Next-Generation Sequencing Services

Market

research finds that the market earned revenues of

$160.0 million

in

2011 and estimates this to reach

$550.0 million

in 2016.

If you are interested in more information on this research, please send an

email to Britni Myers, Corporate Communications, at [e-mail],

with your full name, company name, job title, telephone number, company

email address, company website, city, state and country.

"When new sequencing applications emerge, researchers do not always have

the expertise to conduct them with in-house infrastructure, providing a

significant opportunity for service providers," said Frost & Sullivan Senior

Industry Analyst Christianne Bird. "In particular, the two emerging applications

of RNA-sequencing and exome sequencing are proving lucrative to service

providers."

Genome centers and core facilities account for a larger percentage of the next-

generation sequencing installed base than commercial service providers.

Academic researchers may use core facilities for at-cost services (reagents and

labor only); however, unlike commercial service providers that offer sample-to-

answer services, these facilities do not always provide full bioinformatics and

analysis capabilities.

While users of sequencing core facilities and non-profit genome centers must

have experience with genomic data as well as in-house expertise and software

to conduct analyses, customers of commercial service providers require little to

no familiarity with the technology as they purchase turnkey services with

comprehensive data analysis.

Nevertheless, despite researchers' eagerness to use sequencing services, the

decreasing sequencing costs, influx of new competitors, and increasing

adoption of sequencing in basic laboratories has placed the market in a state of

flux. Commercial sequencing service providers can stay afloat in this dynamic

market by differentiating themselves with value-added services.

In the next five years, next-generation sequencing is expected to gain currency

in clinics for the diagnosis of rare genetic diseases, in clinical trials for patient